European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL).
Khê Hoang-Xuan, Martina Deckert, Andrés J M Ferreri, Julia Furtner, Jaime Gallego Perez-Larraya, Roger Henriksson, Andreas F Hottinger, Benjamin Kasenda, Florence Lefranc, Alexander Lossos, Catherine McBain, Matthias Preusser, Patrick Roth, Roberta Rudà, Uwe Schlegel, Riccardo Soffietti, Carole Soussain, Martin J B Taphoorn, Valérie Touitou, Michael Weller, Jacoline E C Bromberg
Author Information
Khê Hoang-Xuan: APHP, Department of Neurology, Groupe Hospitalier Pitié-Salpêtrière; Sorbonne Université; IHU; ICM. Paris, France.
Martina Deckert: Institute of Neuropathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Andrés J M Ferreri: Lymphoma Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy.
Julia Furtner: Department of Biomedical and Imaging Image-guided Therapy Medical University of Vienna, Vienna, Austria.
Jaime Gallego Perez-Larraya: Health Research Institute of Navarra (IdiSNA), Program in Solid Tumors, Foundation for the Applied Medical Research, Department of Neurology, Clinica Universidad de Navarra, Pamplona, Navarra, Spain.
Roger Henriksson: Department of Radiation Sciences, Oncology, University of Umeå, S-901 85 Umea, Sweden.
Andreas F Hottinger: Department of Oncology and Clinical Neurosciences, CHUV University Hospital Lausanne and University of Lausanne, LausanneSwitzerland.
Benjamin Kasenda: Department of Hematology/Oncology and Palliative Care, Klinikum Stuttgart, Stuttgart, Germany.
Florence Lefranc: Department of Neurosurgery, Hôpital Erasme, Université Libre de Bruxelles, Belgium.
Alexander Lossos: Head, Leslie and Michael Gaffin Center for Neuro-Oncology; Department of Oncology and Neurology; Hadassah-Hebrew University Medical Center; Jerusalem, Israel.
Catherine McBain: Department of Clinical Oncology, The Christie NHS FT; Manchester; United Kingdom.
Matthias Preusser: Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna,Austria. ORCID
Patrick Roth: Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.
Roberta Rudà: Department of Neurology, Castelfranco Veneto/Treviso Hospital, Italy.
Riccardo Soffietti: Division of Neuro-Oncology, Department of Neuroscience, University of Turin, and City of Health and Science University Hospital, Turin, Italy. ORCID
Carole Soussain: Department of Hematology, Institut Curie, Site Saint-Cloud, France and INSERM U932 Institut Curie, PSL Research University, Paris, France.
Martin J B Taphoorn: Department of Neurology, Leiden University Medical Center and Department of Neurology, Haaglanden Medical Center The Hague, The Netherlands.
Valérie Touitou: APHP, Department of Ophtalmology, Groupe Hospitalier Pitié-Salpêtrière; Sorbonne Université. Paris, France.
Michael Weller: Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland. ORCID
Jacoline E C Bromberg: Department of Neuro-Oncology, Erasmus MC University Medical Center Cancer Institute, Rotterdam. The Netherlands.
The management of primary central nervous system (PCNSL) is one of the most controversial topics in neuro-oncology because of the complexity of the disease and the limited number of controlled studies available. In 2021, given recent advances and the publication of practice-changing randomized trials, the European Association of Neuro-Oncology (EANO) created a multidisciplinary task force to update the previously published evidence-based guidelines for immunocompetent adult patients with PCNSL and added a section on immunosuppressed patients. The guideline provides consensus considerations and recommendations for the treatment of PCNSL, including intraocular manifestations and specific management of the elderly. The main changes from the previous guideline include strengthened evidence for the consolidation with ASCT in first-line treatment, prospectively assessed chemotherapy combinations for both young and elderly patients, clarification of the role of rituximab even though the data remain inconclusive, of the role of new agents, and the incorporation of immunosuppressed patients and primary ocular lymphoma. The guideline should aid the clinicians in everyday practice and decision making and serve as a basis for future research in the field.
